Good summary DV.
Holders have every reason to be confident as the collected results taken from the blinded group (a combination of some patients receiving the vaccine and others receiving the placebo) indicated that Professor Frazer has achieved what he set out to....
(This from the ann earlier this year)
*No safety issues have been noted in this cohort of patients. The data remains blinded to protect the integrity of the trial.
*Study participants had a marked decrease in viral lesions (outbreaks) with a drop of over 90% in the monthly rate versus baseline.
This is absolutely huge and represents a quantum leap between what Professor Frazer is achieving and what our nearest competitor, Genocea, has achieved.
Imagine what's possible - HSV 2, page-7
-
- There are more pages in this discussion • 144 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$9.91 |
Change
-0.090(0.90%) |
Mkt cap ! $209.4M | |||
| Open | High | Low | Value | Volume |
| $10.00 | $10.00 | $9.65 | $70.76K | 7.202K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 300 | $9.80 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $9.91 | 475 | 2 |
View Market Depth
| Last trade - 16.10pm 12/11/2024 (20 minute delay) ? |
| AVR (ASX) Chart |